These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 6624480)

  • 1. TXA2-antagonistic properties of agents affecting prostaglandin synthesis or the cyclic nucleotide system in human platelets.
    Kangasaho M; Vapaatalo H
    Acta Pharmacol Toxicol (Copenh); 1983 Aug; 53(2):130-4. PubMed ID: 6624480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor.
    Le Breton GC; Venton DL; Enke SE; Halushka PV
    Proc Natl Acad Sci U S A; 1979 Aug; 76(8):4097-101. PubMed ID: 291066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theophylline inhibits platelet aggregation, prostaglandin and thromboxane production by a mechanism which is independent of cyclic AMP.
    Burns GB; Dodge JA
    Agents Actions; 1984 Jan; 14(1):102-8. PubMed ID: 6322546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandin F2 alpha antagonizes thromboxane A2-induced human platelet aggregation.
    Hung SC; Ghali NI; Venton DL; Le Breton GC
    Prostaglandins; 1982 Aug; 24(2):195-206. PubMed ID: 6293001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
    Ohkubo S; Nakahata N; Ohizumi Y
    Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
    Bertele V; De Gaetano G
    Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
    Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of thromboxane A2/prostaglandin H2 and ADP-induced calcium release in intact platelets.
    Brace LD; Venton DL; Le Breton GC
    Am J Physiol; 1985 Jul; 249(1 Pt 2):H8-13. PubMed ID: 2409821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of thromboxane A2 synthesis in human platelets by coagulation factor Xa.
    Sinha AK; Rao AK; Willis J; Colman RW
    Proc Natl Acad Sci U S A; 1983 Oct; 80(19):6086-90. PubMed ID: 6577468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
    Patscheke H; Stegmeier K
    Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboxane A2/prostaglandin endoperoxide (TXA2/PG-END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor--TXA2/PG-END receptor antagonist.
    Heylen L; De Clerck F; Somers Y; Leysen JE
    Blood Coagul Fibrinolysis; 1991 Oct; 2(5):617-21. PubMed ID: 1838285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets.
    Mais DE; Kochel PJ; Saussy DL; Halushka PV
    Mol Pharmacol; 1985 Aug; 28(2):163-9. PubMed ID: 2991736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism of prostaglandin-mediated responses in platelets and vascular smooth muscle by 13-azaprostanoic acid analogs. Evidence for selective blockade of thromboxane A2 responses.
    Huzoor-Akbar ; Mukhopadhyay A; Anderson KS; Navran SS; Romstedt K; Miller DD; Feller DR
    Biochem Pharmacol; 1985 Mar; 34(5):641-7. PubMed ID: 3156599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets.
    Johnson GJ; Leis LA; Francis GS
    Circulation; 1986 Apr; 73(4):847-54. PubMed ID: 3004784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The generation of TXA2 in human platelet rich plasma and its inhibition by nictindole and prostacyclin.
    Grodzińska L; Marcinkiewicz E
    Pharmacol Res Commun; 1979 Feb; 11(2):133-46. PubMed ID: 375247
    [No Abstract]   [Full Text] [Related]  

  • 16. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.
    Parise LV; Venton DL; Le Breton GC
    J Pharmacol Exp Ther; 1984 Jan; 228(1):240-4. PubMed ID: 6319669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thromboxane A2/prostaglandin H2 mobilizes calcium in human blood platelets.
    Brace LD; Venton DL; Le Breton GC
    Am J Physiol; 1985 Jul; 249(1 Pt 2):H1-7. PubMed ID: 3925795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydropyridine agonist Bay K 8644 inhibits platelet activation by competitive antagonism of thromboxane A2-prostaglandin H2 receptor.
    Johnson GJ; Dunlop PC; Leis LA; From AH
    Circ Res; 1988 Mar; 62(3):494-505. PubMed ID: 2449295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of amrinone on human platelet aggregation: evidence that amrinone does not act through a cyclic nucleotide mechanism in platelet rich plasma.
    Lippton HL; Horwitz PM; McNamara DB; Ignarro LJ; Landry AZ; Hyman AL; Kadowitz PJ
    Prostaglandins Leukot Med; 1985 May; 18(2):193-204. PubMed ID: 3925461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.